Skip Navigation


Rheumatology Advance Access originally published online on June 2, 2009
Rheumatology 2009 48(8):939-943; doi:10.1093/rheumatology/kep139
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
48/8/939    most recent
kep139v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ziswiler, H.-R.
Right arrow Articles by Möller, B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ziswiler, H.-R.
Right arrow Articles by Möller, B.
Related Collections
Right arrow Pharmacology
Right arrow Rheumatoid Arthritis
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

High-resolution ultrasound confirms reduced synovial hyperplasia following rituximab treatment in rheumatoid arthritis

Hans-Rudolf Ziswiler1, Daniel Aeberli1, Peter M. Villiger1 and Burkhard Möller1

1Inselspital, Bern University Hospital, Clinics for Rheumatology, Clinical Immunology and Allergology, Bern, Switzerland.

Correspondence to: Burkhard Möller, Inselspital, Bern University Hospital, Clinics for Rheumatology, Clinical Immunology and Allergology, Freiburgstrasse, 3010 Bern, Switzerland. E-mail: burkhard.moeller{at}insel.ch


   Abstract

Objective. To assess the response of RA patients to rituximab (RTX) treatment using a sensitive imaging technique for synovitis.

Methods. Twenty-three RA patients were treated with two 1000-mg infusions of the B-cell depleting antibody, RTX, in an observational protocol. Clinical response was assessed by the European League Against Rheumatism (EULAR) response criteria. High-resolution grey-scale and colour-coded power Doppler (PD) ultrasonography was performed at baseline and 6 months after RTX. The second to fifth MCP and PIP joints were bilaterally examined with joints in a neutral 0 position from a palmar view and scored from 0 to 3.

Results. Median disease activity score (DAS28) improved from 5.03 to 3.56 (P = 0.001), which corresponded to a EULAR moderate response in 11 of 23 patients and a EULAR good response in another 6 patients. Improved control of disease activity by RTX was also indicated by tapering of median daily corticosteroid doses from 10 to 5 mg, without flare ups. Mean grey-scale scores correlated with the swollen joint count at baseline (r = 0.484, P = 0.022) and month 6 (r = 0.519, P = 0.011). Mean grey-scale scores improved upon RTX from a 0.90 median (range 0.13–1.87) to 0.75 (range 0.19–1.50, P = 0.023). Frequency of PD positive joints was low (6.1%) at baseline and did not significantly change following RTX treatment.

Conclusions. High-resolution grey-scale ultrasonography (US) examination confirmed reduced synovial hyperplasia, but the applied PD method displayed no significant changes. Therefore, only grey-scale US is recommended in follow-up examinations after RTX treatment.

KEY WORDS: Arthritis, B cell, Depletion, Doppler, Grey scale, Hyperplasia, Rheumatoid, Rituximab, Synovitis, Vascularity

Submitted 21 October 2008; revised version accepted 23 April 2009.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.